EC Number   |
Title |
Organism |
|---|
   3.4.17.11 | Characterisation of the carboxypeptidase G2 catalytic site and design of new inhibitors for cancer therapy |
Pseudomonas sp. RS-16 |
| 3.4.17.11 | Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme |
Pseudomonas sp. RS-16 |
| 3.4.17.11 | Production of "biobetter" variants of glucarpidase with enhanced enzyme activity |
Pseudomonas sp. RS-16 |
| 3.4.17.11 | Soluble expression, purification and functional characterisation of carboxypeptidase G2 and its individual domains |
Pseudomonas sp. RS-16 |
| 3.4.17.11 | TAT-mediated intracellular delivery of carboxypeptidase G2 protects against methotrexate-induced cell death in HepG2 cells |
Pseudomonas sp. RS-16 |
| 3.4.17.11 | A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using (19)F magnetic resonance spectroscopy |
Homo sapiens |
| 3.4.17.11 | A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug |
Pseudomonas aeruginosa |
| 3.4.17.11 | Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy |
Pseudomonas sp. |
| 3.4.17.11 | Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin |
Flavobacterium sp. |
| 3.4.17.11 | Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure |
Pseudomonas sp. |
